Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis

Abstract Background The prevalence of gestational diabetes mellitus [GDM] and of its most important predisposing factor, i.e. overweight and obesity, have increased dramatically over the past 20 years. Therefore, the aim of this study was to systematically review the articles on the effect of myo-in...

Full description

Bibliographic Details
Main Authors: Sepideh Mashayekh-Amiri, Sakineh Mohammad-Alizadeh-Charandabi, Somaiyeh Abdolalipour, Mojgan Mirghafourvand
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Online Access:https://doi.org/10.1186/s13098-022-00862-5
_version_ 1818518310060294144
author Sepideh Mashayekh-Amiri
Sakineh Mohammad-Alizadeh-Charandabi
Somaiyeh Abdolalipour
Mojgan Mirghafourvand
author_facet Sepideh Mashayekh-Amiri
Sakineh Mohammad-Alizadeh-Charandabi
Somaiyeh Abdolalipour
Mojgan Mirghafourvand
author_sort Sepideh Mashayekh-Amiri
collection DOAJ
description Abstract Background The prevalence of gestational diabetes mellitus [GDM] and of its most important predisposing factor, i.e. overweight and obesity, have increased dramatically over the past 20 years. Therefore, the aim of this study was to systematically review the articles on the effect of myo-inositol supplementation on the prevention of GDM in pregnant women with overweight and obesity. Methods We conducted a systematic literature search in electronic database (MEDLINE, Cochrane Library, ClinicalTrials.gov, Embase, ProQuest, PubMed, Google scholar, Scopus, Web of science and forward and backward citations) to identify all randomized controlled trials (RCTs) published until 21 December 2021. Finally, Among the 118 identified records, four studies were eligible and were included in this systematic review. The meta-analysis results were reported in the form of odds ratio (OR) to compare the incidence of GDM and pregnancy outcomes. They were also presented in the form of mean difference (MD) to compare fasting glucose (FG), 1-h and 2-h oral glucose tolerance test (OGTT) levels between the two groups. This study was registered on PROSPERO, number CRD42021290570. Results The results showed that the incidence of GDM was significantly lower in the myo-inositol group (OR 0.32, 95% CI 0.21 to 0.48; P < 0.001; I2 = 0%; Moderate certainty evidence). Moreover, FG-OGTT (MD − 2.64 mg/dl, 95% CI − 4.12 to − 1.17; P < 0.001; I2 = 0%; Moderate certainty evidence), 1-h-OGTT (MD − 7.47 mg/dl, 95% CI − 12.24 to − 2.31; P = 0.005; I2 = 27%; Low certainty evidence) and 2-h-OGTT levels (MD − 10.51 mg/dl, 95% CI − 16.88 to − 4.14; P = 0.001; I2 = 59%; Low certainty evidence) in the myo-inositol group were significantly lower than in the control group. Regarding the pregnancy outcomes, the incidence of gestational hypertension and preterm delivery was significantly lower in the myo-inositol group. However, no between-group difference was observed in the other outcomes. Conclusions Based on the results, myo-inositol has shown to be a new and safe preventive strategy in reducing the incidence of GDM and in regulating FG and 1-h and 2-h OGTT levels, and also in reducing the incidence of GDM complications such as preterm delivery and gestational hypertension in pregnant women with overweight and obesity.
first_indexed 2024-12-11T01:08:34Z
format Article
id doaj.art-4458e242a4f1427bb57ed50e54e41c3b
institution Directory Open Access Journal
issn 1758-5996
language English
last_indexed 2024-12-11T01:08:34Z
publishDate 2022-07-01
publisher BMC
record_format Article
series Diabetology & Metabolic Syndrome
spelling doaj.art-4458e242a4f1427bb57ed50e54e41c3b2022-12-22T01:26:07ZengBMCDiabetology & Metabolic Syndrome1758-59962022-07-0114111510.1186/s13098-022-00862-5Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysisSepideh Mashayekh-Amiri0Sakineh Mohammad-Alizadeh-Charandabi1Somaiyeh Abdolalipour2Mojgan Mirghafourvand3Department of Midwifery, Faculty of Nursing & Midwifery, Tabriz University of Medical SciencesDepartment of Midwifery, Faculty of Nursing & Midwifery, Tabriz University of Medical SciencesDepartment of Midwifery, Faculty of Nursing & Midwifery, Tabriz University of Medical SciencesDepartment of Midwifery, Faculty of Nursing & Midwifery, Tabriz University of Medical SciencesAbstract Background The prevalence of gestational diabetes mellitus [GDM] and of its most important predisposing factor, i.e. overweight and obesity, have increased dramatically over the past 20 years. Therefore, the aim of this study was to systematically review the articles on the effect of myo-inositol supplementation on the prevention of GDM in pregnant women with overweight and obesity. Methods We conducted a systematic literature search in electronic database (MEDLINE, Cochrane Library, ClinicalTrials.gov, Embase, ProQuest, PubMed, Google scholar, Scopus, Web of science and forward and backward citations) to identify all randomized controlled trials (RCTs) published until 21 December 2021. Finally, Among the 118 identified records, four studies were eligible and were included in this systematic review. The meta-analysis results were reported in the form of odds ratio (OR) to compare the incidence of GDM and pregnancy outcomes. They were also presented in the form of mean difference (MD) to compare fasting glucose (FG), 1-h and 2-h oral glucose tolerance test (OGTT) levels between the two groups. This study was registered on PROSPERO, number CRD42021290570. Results The results showed that the incidence of GDM was significantly lower in the myo-inositol group (OR 0.32, 95% CI 0.21 to 0.48; P < 0.001; I2 = 0%; Moderate certainty evidence). Moreover, FG-OGTT (MD − 2.64 mg/dl, 95% CI − 4.12 to − 1.17; P < 0.001; I2 = 0%; Moderate certainty evidence), 1-h-OGTT (MD − 7.47 mg/dl, 95% CI − 12.24 to − 2.31; P = 0.005; I2 = 27%; Low certainty evidence) and 2-h-OGTT levels (MD − 10.51 mg/dl, 95% CI − 16.88 to − 4.14; P = 0.001; I2 = 59%; Low certainty evidence) in the myo-inositol group were significantly lower than in the control group. Regarding the pregnancy outcomes, the incidence of gestational hypertension and preterm delivery was significantly lower in the myo-inositol group. However, no between-group difference was observed in the other outcomes. Conclusions Based on the results, myo-inositol has shown to be a new and safe preventive strategy in reducing the incidence of GDM and in regulating FG and 1-h and 2-h OGTT levels, and also in reducing the incidence of GDM complications such as preterm delivery and gestational hypertension in pregnant women with overweight and obesity.https://doi.org/10.1186/s13098-022-00862-5Myo-inositol supplementationGestational diabetes mellitusGDMOverweight and obese
spellingShingle Sepideh Mashayekh-Amiri
Sakineh Mohammad-Alizadeh-Charandabi
Somaiyeh Abdolalipour
Mojgan Mirghafourvand
Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis
Diabetology & Metabolic Syndrome
Myo-inositol supplementation
Gestational diabetes mellitus
GDM
Overweight and obese
title Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis
title_full Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis
title_fullStr Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis
title_full_unstemmed Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis
title_short Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis
title_sort myo inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women a systematic review and meta analysis
topic Myo-inositol supplementation
Gestational diabetes mellitus
GDM
Overweight and obese
url https://doi.org/10.1186/s13098-022-00862-5
work_keys_str_mv AT sepidehmashayekhamiri myoinositolsupplementationforpreventionofgestationaldiabetesmellitusinoverweightandobesepregnantwomenasystematicreviewandmetaanalysis
AT sakinehmohammadalizadehcharandabi myoinositolsupplementationforpreventionofgestationaldiabetesmellitusinoverweightandobesepregnantwomenasystematicreviewandmetaanalysis
AT somaiyehabdolalipour myoinositolsupplementationforpreventionofgestationaldiabetesmellitusinoverweightandobesepregnantwomenasystematicreviewandmetaanalysis
AT mojganmirghafourvand myoinositolsupplementationforpreventionofgestationaldiabetesmellitusinoverweightandobesepregnantwomenasystematicreviewandmetaanalysis